Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica

Executive Summary

With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.


Related Content

Free Imbruvica Program Cleared By HHS Inspector General
Deal Watch: AstraZeneca Buys, Sells And Partners In Busy Week
CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape
Pricing Of Zydelig And Imbruvica Will be Scrutinized After EMA Nod
Imbruvica’s Second-line CLL Claim Still “Powerful And Inclusive”
Biopharma In 2013: A Rising Tide
A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics
Many New Oncology Drugs In 2012, With Prices That Test The Limits


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts